A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.
Y Shinkoda, A Shirahata, K Fukutake, J Takamatsu, M Shima, H Hanabusa, H Mugishima, H Takedani, K Kawasugi, M Taki, T Matsushita, A Tawa, K Nogami, S Higasa, Y Kosaka, T Fujii, M Sakai, M Migita, M Uchiba, K Kawakami, K Sameshima, Y Ohashi, H Saito
Haemophilia : the official journal of the World Federation of Hemophilia 2017;23(1):59-66